Omalizumab for the treatment of severe allergic asthma

Expert Review of Clinical Immunology

Volumn 4, Issue 5, 2008, Pages 543-548

  Menzies Gow, Andrew ^a   Fan Chung, Kian ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Asthma; IgE; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUTICASONE; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ALLERGIC ASTHMA; ANAPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INJECTION SITE REACTION; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 77649175590     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.5.543     Document Type: Review

References (28)

1. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469-478 (2004).
2. Hamelmann E, Takeda K. Role of IgE in the development of allergic airways inflammation and airways hyperresponsiveness - a murine model. Allergy 54, 297-305 (1999).
3. Sunyer J, Anto JM. Relationship between serum IgE and airway responsiveness in adults with asthma. J. Allergy Clin. Immunol. 95, 699-706 (1995).
4. Heaney LH, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 365, 974-976 (2005).
5. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations and unanswered questions. Am. J. Respir. Crit. Care Med. 162, 2341-2351 (2000).
6. Robinson DS, Campbell DA. Systematic assessment of difficult-to-treat asthma. Eur. Respir. J. 22, 478-483 (2003).
7. Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 119, 405-413 (2007).
8. Pollart SM, Chapman MD, Fiocc GP, Rose G, Platts-Mills TA. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J. Allergy Clin. Immunol. 83, 875-882 (1989).
9. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N. Engl. J. Med. 325, 1067-1071 (1991).
10. Peat JK, Toelle BG, Dermand J, Van Den BR, Britton WJ, Woolcock AJ. Serum IgE levels, atopy and asthma in young adults: results from a longitudinal cohort study. Allergy 51, 804-810 (1996).
11. Presta LG, Lahr SJ, Shields RL. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623-2632 (1993).
12. Djukanovic R, Wilson SJ, Kraft M et al. Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170, 583-593 (2004).
13. Corne J, Djukanovic R, Thomas L. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics. J. Clin. Invest. 99, 879-887 (1997).
14. Fahy JV, Fleming HE. The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155, 1828-1834 (1997).
15. Milgrom H, Fick RB. Treatment of allergic asthma with monoclonal anti-IgE antibody. N. Engl. J. Med. 341, 1966-1973 (1999).
16. Soler M, Matz J. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254-261 (2001).
17. Busse W, Corren J. Omalizumab, anti-IgE recombinant humanised monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
18. Ayres JG, Higgins B. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59, 701-708 (2004).
19. Holgate S, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34, 632-638 (2004). (Pubitemid 38534897)
20. Humbert M, Beasley R. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60, 309-316 (2005).
21. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 91, CD003559 (2006).
22. Holgate S, Bosquet J, Wenzel S, Fox H, Kiu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin. 17, 233-240 (2001).
23. Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60, 302-308 (2005).
24. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62, 149-153 (2007). (Pubitemid 46090296)
25. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J. Allergy Clin. Immunol. 120, 1146-1152 (2007).
26. Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr. Med. Res. Opin. 22, 2201-2208 (2006).
27. Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann. Allergy Asthma Immunol. 96, 316-326 (2006).
28. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120(6), 1373-1377 (2007).